Company Overview
Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions. The company pursues acquisitions and partnerships in areas including post-quantum cryptography, zero-trust architecture, and national security technologies. It also develops platforms that integrate artificial intelligence (AI) and quantum computing technologies for autonomous control systems used in unmanned aerial, ground, and underwater vehicles, including drones, self-driving vehicles, and robotic fleets. Quantum Cyber N.V. was formerly known as Mainz Biomed N.V. and changed its name to Quantum Cyber N.V. in April 2026. The company is headquartered in Mainz, Germany.
Recent Developments
- Dec 2025 Revenue of $537.08K (-39.9% YoY); net profit $-16.21M.
- Trailing 12 Months Year-on-year growth — revenue -39.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.45% |
| 1 Year: | -39.92% |
Stock Price Performance
| 1 Year: | -17.44% |
| 6 Months: | +75.31% |
| 3 Months: | -32.38% |
| 1 Month: | -1.39% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 60.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QUCY Quantum Cyber N.V. PHARMA | 1.42 | -0.59 | $119.38M | 0.00% | - | - | 0.45% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Mar 2026 |
|---|---|---|---|
| Revenue | 0 | 286.72K | 0 |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 2.75M | 5.54M | 2.46M |
| Operating Income | -2.75M | -5.35M | -2.46M |
| EBITDA | -2.58M | -5.05M | -2.41M |
| Interest Expense | 30.53K | 184.73K | 15.18K |
| Pretax Income | -2.77M | -5.58M | -2.49M |
| Tax Provision | 0 | 0 | 0 |
| Net Income | -5.00M | -3.34M | -5.08M |
| Diluted EPS | -1.46 | - | -0.43 |
| R&D Expense | 88.75K | - | 59.30K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 529.88K | 895.48K | 893.99K | 537.08K |
| Cost of Revenue | - | 347.73K | 385.82K | 319.11K | 147.29K |
| Gross Profit | - | 182.15K | 509.66K | 574.88K | 389.79K |
| Operating Expenses | - | 26.63M | 27.15M | 19.02M | 13.36M |
| Operating Income | - | -26.44M | -26.64M | -18.45M | -12.97M |
| EBITDA | - | -25.72M | -24.87M | -19.96M | -15.22M |
| Interest Expense | - | 289.32K | 559.58K | 945.54K | 373.46K |
| Pretax Income | - | -26.39M | -26.30M | -21.60M | -16.21M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -26.39M | -26.30M | -21.60M | -16.21M |
| Diluted EPS | - | -74.55 | -64.76 | -21.91 | -2.70 |
| R&D Expense | - | - | - | 5.72M | 4.91M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 20.24M | 15.41M | 13.50M | 5.33M |
| Current Assets | - | 18.38M | 8.98M | 8.02M | 1.84M |
| Cash & Equivalents | - | 17.14M | 7.07M | 6.24M | 889.09K |
| Inventory | - | 175.47K | 613.64K | 372.87K | 216.89K |
| Receivables | - | 63.74K | 93.56K | 33.58K | 17.35K |
| Total Liabilities | - | 6.14M | 12.16M | 7.50M | 4.69M |
| Current Liabilities | - | 4.24M | 9.24M | 6.18M | 3.69M |
| Long Term Debt | 1.94M | 943.21K | 1.03M | - | - |
| Total Debt | - | 3.23M | 7.42M | 3.50M | 2.57M |
| Total Equity | - | 14.10M | 3.25M | 6.00M | 641.60K |
| Shares Outstanding | - | 365.74K | 529.14K | 2.32M | 9.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -14.77M | -21.94M | -17.33M | -10.98M |
| Investing Cash Flow | - | -658.48K | -1.90M | -198.82K | -1.03M |
| Financing Cash Flow | - | 23.94M | 14.23M | 16.79M | 6.76M |
| Capital Expenditure | - | -658.48K | -1.90M | -254.95K | -1.05M |
| Free Cash Flow | - | -15.43M | -23.84M | -17.58M | -12.03M |
| Net Change in Cash | - | 8.52M | -9.61M | -736.99K | -5.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 34.4% | 56.9% | 64.3% | 72.6% |
| Operating Margin % | - | -4,990.6% | -2,975.5% | -2,063.8% | -2,414.0% |
| Net Margin % | - | -4,979.9% | -2,936.5% | -2,416.0% | -3,018.3% |
| ROE % | - | -187.2% | -809.3% | -360.1% | -2,526.6% |
| ROCE % | - | -165.3% | -431.7% | -252.1% | -793.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 0.37% | 84.57K | $116.71K |
| 2 | Virtu Financial LLC | 0.18% | 41.07K | $56.67K |
| 3 | UBS Group AG | 0.11% | 26.11K | $36.03K |
| 4 | Steward Partners Investment Advisory, LLC | 0.09% | 20.00K | $27.60K |
| 5 | Morgan Stanley | 0.05% | 11.19K | $15.44K |
| 6 | Xtx Topco Ltd | 0.05% | 11.39K | $15.72K |
| 7 | Professional Advisory Services, Inc. | 0.04% | 10.00K | $13.80K |
| 8 | Journey Advisory Group, LLC | 0.04% | 10.00K | $13.80K |
| 9 | Keystone Financial Group, Inc. | 0.02% | 5.30K | $7.31K |
| 10 | Tower Research Capital LLC (TRC) | 0.02% | 4.00K | $5.52K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QUCY
Why Is QUCY Stock Rising Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNLW9mY0JRX3Y1RGtibldqX3RKaTdlM3g5WjBjRGRoSkhOTVRGdlRyMHJ0TkdBN0pOVWRiQlRaVGZBVnhCQmpDTTZRTkhKMmpzdWhVNERCd0NtMmVDQ1Vac3ltVTlzN1NIYklXaS0tWUtmUWM4Vko2RUwzVk9yNV91cXZ4M1cwZndEN08xX3…
Eight Nvidia chips are training AI for drone swarms - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQWnFJREx0eDloYkx4eUJPb2hPZEU5bThSR28tWnlMdU9HdWUyQlVDUGRjZXhzMnVWOUY5OUZqLThVRkNJR2lVcjRZT0NfLThBdjlJWExNcGtUX3h6X0xQN2NJUXNpY094eXhScmFVenlScjZmNndRZmpLLXh4TWhoM0NYQVg5WkExWTJMa2…
Why Did QUCY Stock Surge 70% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQcXJYN3BGTUdPWldyMjV3OTBQVGFzay0xYV9QMzQ4czdWVG1lcEs2U2puak1QNHZtQkJDMS05N2JuY2JTd2s3a1RVYU1yc2xzZjJkMGVNOEYtdUR5T0xSTjRtckVZdUdVNW0tczFnaHdORDk2QmdTSUtEc3RpYmZNLVlwcTBTSlM1ZGQwWm…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1RUXdMTTROVzZOa0xQVW82NU9CMS1XcFcwWGZLMVpia1hMS1I2Ul9DWkFWVjlKTDZfckxQdXZvNlBYTl83T0NMQXU0YmZwVmZj?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
QUCY Stock Continues Its Double-Digit Rally For A Second Day: What’s Behind The Momentum? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPQ3ZUQlhtQ0otZHpFbG5felBlUUNvbDBFYnZKSVBISlNqZUhNNFVhSGdfZ1JJRHVVd045YjFrNm5QUE1sR050dUZ0X2hCbjVLRmhpNE1oX3pndnY4RHJZMzUxak9udTdZZVl0R05KVHY3RVEzZkNHakNwdkQyR29EU2tPNlgzcTdYTGVZVD…
QUCY Stock Prediction: Is Quantum Cyber The Next Defense Giant? Rays - Blue Jays (1zLm7jzVdo) - Mshale
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE1lNUZ2cnY1bXdhdnotVnRLQVZwRlB6UEd0aTUyYVBwTjZ3NElEci14dkhXakltZG9GTUsxZDZwSXhnN25xbDlveTFPYzIxZ28zZ241UHllQU51YVk?oc=5" target="_blank">QUCY Stock Prediction: Is Quantum Cyber The …
QUCY — Frequently Asked Questions
What is the current share price of Quantum Cyber N.V. (QUCY)?
As of 2026-09-19 21:16 PDT, Quantum Cyber N.V. (QUCY) trades at $1.42 on NasdaqCM. Its 52-week range is $0.32 to $3.56.
What is the market capitalisation of QUCY?
Quantum Cyber N.V. (QUCY) has a market capitalisation of $119.38M on NasdaqCM.
What is the P/E ratio of QUCY?
QUCY trades at a trailing price-to-earnings (P/E) ratio of -0.59. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.70.
Is QUCY a good stock to buy?
This page provides a data-driven analysis of Quantum Cyber N.V. (QUCY), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.